When was Bluebird Bio founded?

Bluebird Bio was founded in 1992 and raised its 1st funding round 12 years after it was founded.

Where is Bluebird Bio located?

Bluebird Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Bluebird Bio have?

As of Sep 30, 2026, the latest employee count at Bluebird Bio is 307.

Is Bluebird Bio a funded company?

Bluebird Bio is a funded company, having raised a total of $136M across 9 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 04, 2004.

How much is Bluebird Bio worth?

The last known valuation of Bluebird Bio was $***** as of Dec 17, 2025.

When was the latest funding round of Bluebird Bio?

Bluebird Bio's latest funding was a $***** Post IPO round on Jun 03, 2022, with participation from 1 investor.

Where does Bluebird Bio rank among its competitors?

Bluebird Bio ranks 21st amongst 3604 active competitors, of which 1209 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Bluebird Bio?

Bluebird Bio's top competitors include Jazz Pharmaceuticals, BridgeBio and BeiGene. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Bluebird Bio - 2026 Company Profile, Funding, Competitors & Financials

Bluebird Bio is an acquired company based in Cambridge (United States), founded in 1992. It operates as a Developer of gene therapies for severe genetic and rare diseases. Bluebird Bio has raised $136M in funding from investors like TVM Capital, Third Rock Ventures and Easton Capital Investment Group, with last known valuation of $*****. The company has 3604 active competitors, including 1209 funded and 865 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BridgeBio and BeiGene.

Company Details

Developer of gene therapies for severe genetic and rare diseases. The company's products include Lenti-D for Childhood Cerebral Adrenoleukodystrophy (ALD) and LentiGlobin for rare hemoglobinopathies. The company's other products for multiple myeloma and HPV-associated cancer are in the preclinical stage. The company is also using homing endonuclease and megaTAL gene-editing technologies in a variety of potential applications and disease areas, including hematology and oncology.

Website: bluebirdbio.com
Social
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

1992

Location

Cambridge, United States

Stage

Acquired

Total Funding

$136M in 9 rounds

Latest Funding Round

Post IPO, Jun 03, 2022, $*****

Last Known Valuation

$***** as on Dec 17, 2025

Investors

TVM Capital & 11 more

Ranked

21^st among 3604 active competitors

Employee Count

307 as on Sep 30, 2026

Investment & Acquisitions

Pregenen & 1 more

Similar Companies

Jazz Pharmaceuticals & 3340 more

Exit Details

Acquired by The Carlyle Group (Feb 21, 2025)

View Bluebird Bio's full profile

Bluebird Bio is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Bluebird Bio, Inc. CIN: 786164 , United States, Active	Apr 25, 2024	-	-	-
Bluebird Bio, Inc. CIN: 133680878 , United States, Active	Dec 26, 999	-	272 (As on Dec 31, 2024)	-

Bluebird Bio got acquired by The Carlyle Group and SK Capital on Feb 21, 2025 at an acquisition amount of $*****.

Click here to take a look at Bluebird Bio's acquisition in detail

Bluebird Bio has raised a total funding of $136M over 9 rounds. Its first funding round was on Oct 04, 2004. Its latest funding round was a Post IPO round on Jun 03, 2022 for $*****. 1 investor participated in its latest round. Bluebird Bio has 12 institutional investors.

Here is the list of recent funding rounds of Bluebird Bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 03, 2022	7003706	Post IPO	8017233	7153074	9680370	3693242
Sep 08, 2021	5668880	Post IPO	4192034	8081542	6730892	9234714
Oct 27, 2012	8736110	Grant (prize money)	5481628	2749107	4432455	4077887

Access funding benchmarks and valuations. Sign up today!

View details of Bluebird Bio's funding rounds and investors

Bluebird Bio's employee count trend

Bluebird Bio has 307 employees as of Sep 26. Here is Bluebird Bio's employee count trend over the years:

Uncover Bluebird Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bluebird Bio include Jazz Pharmaceuticals, BridgeBio and BeiGene. Here is the list of Top 10 competitors of Bluebird Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
3rd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
4th	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
5th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
6th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
7th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
8th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, T. Rowe Price & 6 others	73/100
9th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
10th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
21st	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	Abn Amro, Thecarlylegroup.fr & 10 others	51/100